Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Asimina T. Georges"'
Autor:
Kathlyn A. Parker, Asimina T. Georges
Publikováno v:
ChemInform. 31
Nucleophilic 1,2-addition of lithiated glycal 9b to functionalized quinone 7 provided, after reductive aromatization, C-arylglycoside 11b. Treatment with mCPBA afforded the tricyclic papulacandin framework. Alternatively, hydroboration gave the chaet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98b8372048e44e152754523931d92682
https://doi.org/10.1002/chin.200021235
https://doi.org/10.1002/chin.200021235
Autor:
Asimina T. Georges, Kathlyn A. Parker
Publikováno v:
Organic Letters. 2:497-499
[reaction: see text] Nucleophilic 1,2-addition of lithiated glycal 9b to functionalized quinone 7 provided, after reductive aromatization, C-arylglycoside 11b. Treatment with mCPBA afforded the tricyclic papulacandin framework. Alternatively, hydrobo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::581e01571bb7a1313a32590fb9b8ab40
https://doi.org/10.1021/ol991346l
https://doi.org/10.1021/ol991346l
Autor:
Asimina T. Georges, Julian Adams, James R Porter, Janid A. Ali, Emmanuel Normant, Yun Gao, Roger H. Pak, Jie Ge, Vito J. Palombella, Thomas T. Tibbitts, Louis Grenier, Marlene S Dembski, Jeffrey K. Tong, Jon Patterson, Jens Sydor
Publikováno v:
Journal of medicinal chemistry. 49(15)
17-Allylamino-17-demethoxygeldanamycin (17-AAG)1 is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clinical trials for the treatment of cancer. However, 17-AAG faces challenging formulation issues due to its poor solu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0ce3785fbf55bd027b3985ccdd2857
https://pubmed.ncbi.nlm.nih.gov/16854066
https://pubmed.ncbi.nlm.nih.gov/16854066
Autor:
Jon Patterson, Vito J. Palombella, James H. Porter, David Grayzel, Asimina T. Georges, John P. Barrett, Christine Pien, Adams Julian, Jennie Ge, Jeffrey K. Tong, Kenneth C. Anderson, Kerry Spear, Roger H. Pak, Janid Ali, Jebecka Hudak, Constantine S. Mitsiades, Emmanuel Normant, James Homer Wright, Melissa Pink, Louis Grenier, Jens Sydor, Michael Foley, Yun Gao, Junbiao Sang
Publikováno v:
Blood. 104:4922-4922
IPI-504 is a novel inhibitor of Hsp90 based on the geldanamycin pharmacophore. When placed in rat, monkey, and human blood, IPI-504 rapidly converts to the known and well-studied compound 17-allylamino-17-demethoxy-geldanamycin (17-AAG). 17-AAG is th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd62aefb41f6324e4b5334429ce29775
https://doi.org/10.1182/blood.v104.11.4922.4922
https://doi.org/10.1182/blood.v104.11.4922.4922